Literature DB >> 22487468

Losses at chromosome 4q are associated with poor survival in operable ductal pancreatic adenocarcinoma.

A M Luebke1, M Baudis, H Matthaei, Y K Vashist, P E Verde, S B Hosch, A Erbersdobler, C A Klein, J R Izbicki, W T Knoefel, N H Stoecklein.   

Abstract

Here we tested the prognostic impact of genomic alterations in operable localized pancreatic ductal adenocarcinoma (PDAC). Fifty-two formalin-fixed and paraffin-embedded primary PDAC were laser micro-dissected and were investigated by comparative genomic hybridization after whole genome amplification using an adapter-linker PCR. Chromosomal gains and losses were correlated to clinico-pathological parameters and clinical follow-up data. The most frequent aberration was loss on chromosome 17p (65%) while the most frequent gains were detected at 2q (41%) and 8q (41%), respectively. The concomitant occurrence of losses at 9p and 17p was found to be statistically significant. Higher rates of chromosomal losses were associated with a more advanced primary tumor stage and losses at 9p and 18q were significantly associated with presence of lymphatic metastasis (chi-square: p = 0.03, p = 0.05, respectively). Deletions on chromosome 4 were of prognostic significance for overall survival and tumor recurrence (Cox-multivariate analysis: p = 0.026 and p = 0.021, respectively). In conclusion our data suggest the common alterations at chromosome 8q, 9p, 17p and 18q as well as the prognostic relevant deletions on chromosome 4q as relevant for PDAC progression. Our comprehensive data from 52 PDAC should provide a basis for future studies with a higher resolution to discover the relevant genes located within the chromosomal aberrations identified.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 22487468     DOI: 10.1016/j.pan.2011.11.001

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  3 in total

1.  RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma.

Authors:  Ying-Ying Liang; Li-Sheng Zheng; Yuan-Zhong Wu; Li-Xia Peng; Yun Cao; Xue Cao; Ping Xie; Bi-Jun Huang; Chao-Nan Qian
Journal:  Cell Cycle       Date:  2014-03-10       Impact factor: 4.534

2.  Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer.

Authors:  Faik G Uzunoglu; Ebba Dethlefsen; Annkathrin Hanssen; Michaela Wrage; Lena Deutsch; Katharina Harms-Effenberger; Yogesh K Vashist; Matthias Reeh; Guido Sauter; Ronald Simon; Maximillian Bockhorn; Klaus Pantel; Jakob R Izbicki; Harriet Wikman
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

3.  HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.

Authors:  Feng Xue; Brandon W Higgs; Jiaqi Huang; Chris Morehouse; Wei Zhu; Xin Yao; Philip Brohawn; Zhan Xiao; Yinong Sebastian; Zheng Liu; Yun Xia; Dong Shen; Mike Kuziora; Zhengwei Dong; Hulin Han; Yi Gu; Jianren Gu; Qiang Xia; Yihong Yao
Journal:  J Transl Med       Date:  2015-12-11       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.